Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.78 |
| ▸ | NPC1 | O15118 | 3/20 | 0.78 |
| ▸ | RAB9A | P51151 | 2/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.78 |
| ▸ | RELA | Q04206 | 1/20 | 0.78 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797592 | 0.89 | MAPT (0.63) | MAPTMAPK1NPC1RAB9ANFKB1 | |
| SCHEMBL527627 | 0.88 | RAB9A (1.00) | MAPTMAPK1NPC1RAB9ANFKB1 | |
| SCHEMBL6805283 | 0.87 | MAPT (0.70) | MAPTMAPK1NPC1RAB9ANFKB1 | |
| SCHEMBL6803111 | 0.86 | MAPT (0.61) | MAPTMAPK1NPC1RAB9ANFKB1 | |
| SCHEMBL6797002 | 0.84 | MAPT (0.58) | MAPTMAPK1NPC1RAB9ANFKB1 | |
| SCHEMBL17815792 | 0.84 | MAPT (0.67) | MAPTMAPK1NPC1RAB9ANFKB1 | |
| SCHEMBL30777226 | 0.84 | MAPT (0.57) | MAPTMAPK1NPC1RAB9ANFKB1 | |
| SCHEMBL27168488 | 0.84 | MAPT (0.57) | MAPTMAPK1NPC1RAB9ANFKB1 | |
| SCHEMBL2781396 | 0.83 | NPC1 (0.67) | MAPTMAPK1NPC1RAB9ANFKB1 | |
| SCHEMBL6798538 | 0.83 | MAPT (0.56) | MAPTMAPK1NPC1RAB9ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| CN-1051548-C | Heterobicyclic derivatives, pharmaceutical compositions containing them, process for preparing them and their use | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| CN-1250776-A | Heterodicyclic compound derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | MAPT 1885/4885MAPK1 124/4885NPC1 1743/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | MAPT 1885/4885MAPK1 124/4885NPC1 1743/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | MAPT 1885/4885MAPK1 124/4885NPC1 1743/4885 |
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | MAPT 4677/4885MAPK1 2643/4885NPC1 875/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | MAPT 1885/4885MAPK1 124/4885NPC1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.